ArticleScientific reports2025
Targeting ESKAPE pathogens with ZnS and Au@ZnS Core-Shell nanoconjugates for improved biofilm control.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
The escalating prevalence of antibiotic-resistant infections and implant-related complications caused by biofilm-forming pathogens from the ESKAPE group, as identified by the World Health Organization (WHO), underscores the urgent need for innovative anti-biofilm strategies. Their occurrence on medical implants & prosthetic devices, as well as nosocomial infections in co-morbid patients, has become a global concern in the healthcare sector. In response, we investigated the efficacy of as-synthesized ZnS quantum dots (ZnS QD) and novel Au@ZnS nanoconjugates (Au@ZnS NC) against a spectrum of ESKAPE pathogens. The present study aimed to elucidate their antibacterial and anti-biofilm efficacy, focusing on Acinetobacter baumannii, Enterobacter cloacae, Staphylococcus epidermidis, Enterococcus faecium, Proteus mirabilis, Pseudomonas aeruginosa, Enterococcus faecalis, Staphylococcus aureus and Enterobacter aerogenes pathogens. The novel synthesis and application of ZnS QD and Au@ZnS core-shell NC demonstrate exceptional anti-biofilm efficacy, stability, and solubility in aqueous environments. Utilizing minimum inhibitory concentration (MIC) assays, tube dilution, and biofilm formation assay, we noticed a significant reduction in biofilm formation and extracellular polymeric substances (EPS) production upon treatment with Au@ZnS NC, even at low concentrations. Further investigations, including cell permeability assay, reactive oxygen species analysis, and comet analysis, demonstrated that the Au@ZnS NC induced oxidative stress, destabilizing cell structure, macromolecule destruction, and DNA strand breakage. Notably, Au@ZnS nanoconjugates effectively inhibited biofilm formation within 24 h across all tested strains, outperforming ZnS quantum dots. This research highlights the potential of Au@ZnS nanoconjugates to revolutionize infection control on medical devices and implants, offering a promising solution to the global healthcare challenge posed by biofilm-forming pathogens as we also observed minimal bacterial colonization on Au@ZnS treated urinary catheters.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.